ARMO Biosciences is a biopharma company, developing immunotherapies for the treatment of cancer, fibrosis, cardiovascular and inflammatory diseases.
In early 2013, ARMO licensed the PEGylated human IL-10 polypeptide from Merck and purchased the Prevascar (rHuIL-10) asB sets from Renovo Ltd.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/armo-biosciences” connections=”true” suffix=””]
In Feb. 2016, ARMO raised $50 Mn in Series C private financing. The Series C financing included all of ARMOs existing investors, including Kleiner Perkins Caufield & Byers (KPCB), OrbiMed, DAG Ventures and NanoDimension, as well as new investors HBM Healthcare Investments, GV (formerly Google Ventures), Celgene Corporation, Industrial Investors Group.
In May 2014, ARMO closed $30 Mn in Series B financing, led by NanoDimension, Kleiner Perkins Caufield & Byers, OrbiMed and DAG Ventures. Prior in Nov. 2013, ARMO raised $20 Mn in a Series A round.
Recover your password.
A password will be e-mailed to you.